A new COVID-19 vaccine aims to stop the entire novel coronavirus — not just deliver antibodies to stop the virus’ spike protein.
According to Al Jazeera, the French pharmaceutical company Valneva has created a COVID-19 vaccine that “stimulates an immune response to the whole virus, and that might give it an edge over its competitors.”
- Currently, other coronavirus vaccines are creating “an immune response that targets only the coronavirus spike protein,” Al Jazeera said.
- “It’s different because it uses the tried and true method of taking the whole coronavirus and inactivating it so it can no longer cause disease. It is then combined with an adjuvant, a substance that helps it effectively penetrate human cells,” reports Al Jazeera.
- This is similar to the vaccines used for flu and polio.
The vaccine is making headlines for successful trials. The vaccine reportedly offered greater protection against COVID-19 compared to the AstraZeneca vaccine in a clinical trial, prompting the company to prepare for approval from European regulators, Bloomberg reported.
Scientists are working hard to find new ways to stop the coronavirus. As I wrote for Deseret News, researchers at the Duke Human Vaccine Institute and the Gillings School of Global Public Health at the University of North Carolina at Chapel Hill discovered an antibody that could stop COVID-19 and other coronavirus variants.